pharma · Colorectal Carcinoma · Glioblastoma
Photonamic GmbH & Co. KG
Photonamic GmbH & is a pharma organization headquartered in EU. Primary therapeutic focus areas include Colorectal Carcinoma, Glioblastoma. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent reco
Phase 2 · small molecule · Glioblastoma
Gliolan (5-aminolevulinic acid hydrochloride) is a small-molecule antineoplastic agent developed by Photonamic GmbH & Co. KG for the treatment of glioblastoma, specifically newly diagnosed supratentorial IDH wild-type glioblastoma. The drug is currently in Phase 2 development, with active evaluation of its feasibility
Internal code GL 01
Gliolan (5-aminolevulinic acid hydrochloride) is a small-molecule antineoplastic agent developed by Photonamic GmbH & Co. KG for the treatment of glioblastoma, specifically newly diagnosed supratentorial IDH wild-type glioblastoma. The drug is currently in Phase 2 development, with active evaluation of its feasibility for stereotactic interstitial photodynamic therapy (iPDT) in adult patients. Gliolan has already achieved regulatory approval in the European Union under two marketing authorization holders: Biofrontera Bioscience GmbH (approved 30 October 2024, EMEA/H/C/002204) and Photonamic GmbH & Co. KG (approved 18 February 2026, EMEA/H/C/000744), both under the therapeutic classification of antineoplastic and immunomodulating agents (L01). The current Phase 2 trial, identified by NCT 2023-510024-79-00, focuses on assessing the feasibility of the photodynamic therapy approach in this patient population. Gliolan represents a specialized approach to glioblastoma management through photodynamic therapy, addressing a disease with significant unmet medical needs and limited treatment options.
Glioblastoma remains one of the most aggressive and lethal primary brain tumors, with poor prognosis despite current standard-of-care treatments including surgery, radiation, and chemotherapy. IDH wild-type glioblastomas represent the majority of newly diagnosed cases and carry particularly poor outcomes. The unmet medical need for improved therapeutic options is substantial, as median overall survival remains limited even with multimodal therapy. Gliolan's photodynamic therapy approach offers a potentially novel mechanism to address this challenge, leveraging light-activated therapy to target tumor tissue with potential for improved local control and reduced systemic toxicity compared to conventional chemotherapy. The European regulatory approvals for Gliolan indicate clinical validation of this approach, though the ongoing Phase 2 trial suggests further evaluation of feasibility and efficacy is warranted. The competitive landscape for glioblastoma includes various antineoplastic agents, though most approved competitors listed (Imbruvica, Afinitor, Kyprolis, Vyxeos) are not specifically indicated for glioblastoma, indicating limited direct competition in this specific indication. The commercial significance lies in addressing a high-mortality disease with limited treatment alternatives and the potential for photodynamic therapy to establish a new treatment paradigm in glioblastoma management.
Drug Class: Antineoplastic and immunomodulating agent (ATC L01)
Active Pharmaceutical Ingredient: 5-aminolevulinic acid hydrochloride
Brand Name: AMELUZ (also marketed as Gliolan for the 30 mg/ml powder for oral solution formulation)
Modality: Small molecule
Mechanism of Action: Not yet disclosed in available facts
Target: Not yet disclosed in available facts
Route of Administration: Oral (powder for oral solution)
Therapeutic Application: Photodynamic therapy agent for glioblastoma
Regulatory Status: Approved in European Union under two marketing authorization holders (Biofrontera Bioscience GmbH and Photonamic GmbH & Co. KG)
Related Therapies: 5-aminolevulinic acid is a naturally occurring compound that serves as a precursor to protoporphyrin IX, which is activated by light to generate reactive oxygen species for photodynamic therapy applications
Also known as: GBM, GBM (glioblastoma), WHO grade IV glioma, glioblastoma (disease), glioblastoma multiforme, glioblastoma multiforme (disease)
Prevalence: Point prevalence: 1-9 / 100 000 (Worldwide) — source: Orphanet, validated.
The most malignant astrocytic tumor (WHO grade IV). It is composed of poorly differentiated neoplastic astrocytes and it is characterized by the presence of cellular polymorphism, nuclear atypia, brisk mitotic activity, vascular thrombosis, microvascular proliferation and necrosis. It typically affects adults and is preferentially located in the cerebral hemispheres. It may develop from diffuse astrocytoma WHO grade II or anaplastic astrocytoma (secondary glioblastoma, IDH-mutant), but more frequently, it manifests after a short clinical history de novo, without evidence of a less malignant precursor lesion (primary glioblastoma, IDH- wildtype). (Adapted from WHO)
ClinicalTrials.gov lists 877 registered studies for Glioblastoma (AACT aggregate).
Phase breakdown: NA (252), PHASE2 (223), PHASE1 (206), PHASE1/PHASE2 (86), EARLY_PHASE1 (49), PHASE3 (45), PHASE2/PHASE3 (11), PHASE4 (5)
Common investigational therapies:
Disease data sourced from MONDO Disease Ontology (MONDO:0018177), Orphanet — glioblastoma, NCT00001148, NCT00001171, NCT00009035, NCT00028158, NCT00029783, AACT (ClinicalTrials.gov aggregate), ClinicalTrials.gov, Open Targets Platform (CC BY 4.0).
Phase 2 trial initiated
Evaluation of feasibility of PD L 506 for stereotactic interstitial photodynamic therapy (iPDT) in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma (NCT 2023-510024-79-00).
EMA approval - Biofrontera
Gliolan approved by European Medicines Agency under marketing authorization holder Biofrontera Bioscience GmbH (EMEA/H/C/002204).
EMA approval - Photonamic
Gliolan approved by European Medicines Agency under marketing authorization holder Photonamic GmbH & Co. KG (EMEA/H/C/000744).
The competitive landscape for glioblastoma treatment is limited, with most approved antineoplastic agents listed in the facts serving other oncology indications rather than glioblastoma specifically. Approved competitors include Imbruvica (Janssen-Cilag), Afinitor (Novartis), Kyprolis (Amgen), Vyxeos Liposomal (Jazz Pharmaceuticals), and various chemotherapy agents such as Paclitaxel Accord. However, these agents are not specifically indicated for glioblastoma in the available facts, suggesting that Gliolan may occupy a relatively differentiated position within the glioblastoma treatment space through its photodynamic therapy mechanism. The photodynamic therapy approach represents a distinct therapeutic modality compared to conventional chemotherapy, targeted therapy, or immunotherapy approaches employed by most competing agents. Gliolan's European regulatory approvals under two separate marketing authorization holders (Biofrontera Bioscience GmbH and Photonamic GmbH & Co. KG) indicate established market presence in Europe. The ongoing Phase 2 trial suggests that clinical validation of feasibility and efficacy remains an active priority, potentially positioning Gliolan for expanded clinical adoption if trial results support its use in newly diagnosed IDH wild-type glioblastoma.
| Therapy | Company | Mechanism | Status |
|---|---|---|---|
| PFIZER AUSTRALIA PTY LTD | Pfizer Australia Pty Ltd | — | approved |
| IMBRUVICA | Janssen-Cilag Pty Ltd | — | approved |
| AFINITOR | Novartis Pharmaceuticals | — | approved |
| LYSODREN | S.A. | — | approved |
| INLYTA | Pfizer Australia Pty Ltd | — | approved |
| LYNOZYFIC | Regeneron UK Limited | — | approved |
| VYXEOS LIPOSOMAL (PREVIOUSLY VYXEOS) | Jazz Pharmaceuticals Ireland Limited | — | approved |
| KYPROLIS | Amgen | — | approved |
| UNITUXIN | United Therapeutics Europe Ltd | — | approved |
| PACLITAXEL ACCORD | Accord Healthcare Pty. | — | approved |
| OFEV | Boehringer Ingelheim Pty Ltd | — | approved |
| ARX-IMATINIB | Alphapharm Pty Ltd | — | approved |
| CARMUSTINE | — | Glutathione reductase inhibitor | Approved |
| BEVACIZUMAB | — | Vascular endothelial growth factor A inhibitor | Approved |
| TRABEDERSEN | — | Transforming growth factor beta-2 mRNA antisense inhibitor | Phase 3 |
| TOFACITINIB | — | Janus Kinase (JAK) inhibitor | Phase 3 |
| RINDOPEPIMUT | — | Epidermal growth factor receptor erbB1 vaccine antigen | Phase 3 |
| OMBIPEPIMUT-S | — | Wilms tumor protein vaccine antigen | Phase 3 |
| NIVOLUMAB | — | Programmed cell death protein 1 inhibitor | Phase 3 |
| NIMOTUZUMAB | — | Epidermal growth factor receptor erbB1 inhibitor | Phase 3 |
Additional associated therapies sourced from Open Targets Platform (CC0), linked to NovaPharmaNews drug profiles where matched.
European Union (EMA):
United States FDA: Regulatory status not yet disclosed
Japan (PMDA): Regulatory status not yet disclosed
China (NMPA): Regulatory status not yet disclosed
Gliolan (5-aminolevulinic acid hydrochloride) is used for the treatment of glioblastoma, specifically newly diagnosed supratentorial IDH wild-type glioblastoma, through photodynamic therapy.
Yes, Gliolan is approved in the European Union under two marketing authorization holders: Biofrontera Bioscience GmbH (approved 30 October 2024) and Photonamic GmbH & Co. KG (approved 18 February 2026). Regulatory status in the US, Japan, and China is not yet disclosed.
Gliolan contains 5-aminolevulinic acid hydrochloride, which serves as a precursor to protoporphyrin IX. When activated by light during stereotactic interstitial photodynamic therapy (iPDT), it generates reactive oxygen species to target tumor tissue. Specific molecular targets and detailed mechanism of action are not yet disclosed.
Gliolan is developed by Photonamic GmbH & Co. KG. It is marketed in the European Union by both Photonamic GmbH & Co. KG and Biofrontera Bioscience GmbH as marketing authorization holders.
Gliolan is currently in Phase 2 development, with an active trial (NCT 2023-510024-79-00) evaluating the feasibility of photodynamic therapy in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma.
Trial NCT 2023-510024-79-00 is evaluating the feasibility of PD L 506 (Gliolan) for stereotactic interstitial photodynamic therapy (iPDT) in adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma. Trial design details and results are not yet disclosed.
Gliolan is indicated for glioblastoma, specifically newly diagnosed supratentorial IDH wild-type glioblastoma, using photodynamic therapy as the treatment approach.
Gliolan is a small-molecule antineoplastic agent classified under therapeutic class L01 (Antineoplastic and immunomodulating agents).
Gliolan is administered as a 30 mg/ml powder for oral solution. The powder is reconstituted to create an oral solution for patient administration.
Glioblastoma, particularly IDH wild-type glioblastoma, has poor prognosis with limited treatment options despite current standard-of-care therapies. Gliolan offers a photodynamic therapy approach that may provide improved local tumor control with potentially reduced systemic toxicity.
While various antineoplastic agents are approved (Imbruvica, Afinitor, Kyprolis, Vyxeos, and others), most are not specifically indicated for glioblastoma. Gliolan's photodynamic therapy mechanism represents a differentiated approach with limited direct competition in this specific indication.
Gliolan is classified as an antineoplastic and immunomodulating agent (ATC L01), a class of drugs used to treat cancer and modulate immune responses.
The active pharmaceutical ingredient in Gliolan is 5-aminolevulinic acid hydrochloride, a naturally occurring compound that serves as a precursor to protoporphyrin IX for photodynamic therapy applications.
Regulatory status of Gliolan in the United States is not yet disclosed in available facts. The drug is currently approved in the European Union.
Gliolan has two EMA product numbers: EMEA/H/C/002204 (Biofrontera Bioscience GmbH) and EMEA/H/C/000744 (Photonamic GmbH & Co. KG).
Gliolan targets adult patients with newly diagnosed supratentorial IDH wild-type glioblastoma, a particularly aggressive form of brain cancer.
Gliolan 30 mg/ml powder for oral solution. → Drug → Target → Indication → Company → Trials → Competitors
Strategic Implications: Photonamic's dual European regulatory approvals (through both Biofrontera and its own entity) suggest a complex commercialization strategy, potentially involving licensing or partnership arrangements. The Phase 2 trial continuation despite EMA approvals indicates that clinical evidence generation remains a priority, possibly to support expanded indications, additional geographic approvals, or to establish a more robust evidence base for clinical adoption.
Competitive Implications: Gliolan's photodynamic therapy mechanism represents a differentiated approach within the glioblastoma treatment landscape, where most competing agents employ conventional chemotherapy or targeted mechanisms. The lack of specific glioblastoma indications for most listed competitors suggests limited direct competition in this indication, though broader oncology agents may be used off-label or in combination regimens.
Future Catalysts: Completion and publication of the Phase 2 feasibility trial (NCT 2023-510024-79-00) represents the primary near-term catalyst. Additional catalysts may include: regulatory submissions in non-EU jurisdictions (FDA, PMDA, NMPA), expansion to additional glioblastoma subtypes or patient populations, and clinical adoption data from European markets. Potential label expansions or combination therapy trials could further expand the commercial opportunity.
Expected Milestones: Specific dates for Phase 2 trial completion, interim analyses, or regulatory submissions in other jurisdictions are not yet disclosed. Monitoring for trial results publication and regulatory filings in major markets (US, Japan, China) will be essential for tracking program progression.
Concise, citable answers optimized for AI answer engines.
Intelligence compiled from public regulatory and clinical sources (FDA, EMA, ClinicalTrials.gov and company disclosures). Figures may be editorial or analyst estimates; verify against primary sources before relying on them.